Budoprutug (CD19 Antibody)

May 14, 2026 — Climb Bio, Inc. (Nasdaq: CLYM) announced it will present new clinical data on budoprutug at the European Hematology Association (EHA) 2026 Congress in Stockholm (June 11–14, 2026). The presentation will include safety, B‑cell depletion, and initial platelet data from the low-dose cohort (250 mg at 24 weeks) in an ongoing Phase 1b/2a trial of budoprutug, a low‑fucosylated anti‑CD19 monoclonal antibody, in previously treated adults with primary immune thrombocytopenia (ITP). Poster details: “Budoprutug… Initial Phase 1b Study Results,” Poster Session 2, PS2440, June 13, 2026 (18:45–19:45 CEST).

Business/clinical significance: The release signals progress and forthcoming readouts for budoprutug in ITP, supporting continued clinical development across B‑cell mediated diseases (also being studied in primary membranous nephropathy and systemic lupus erythematosus), with an in-development subcutaneous formulation noted.